Please login to the form below

Not currently logged in
Email:
Password:

Allergan acquires Vicept

Allergan has entered into an agreement to buy privately-owned Vicept Therapeutics

California-based pharmaceutical firm Allergan is set to acquire privately-owned Vicept Therapeutics for an undisclosed sum.

The agreement, which is expected to be finalised in the third quarter of 2011, includes a $75m cash upfront payment and up to $200m of milestone payments.

Dr Scott M Whitcup, executive vice president and chief scientific officer of Allergan, said: "The acquisition of Vicept Therapeutics will further enhance our dermatology research and development pipeline, and matches our corporate strategy and long-standing commitment to patients suffering from skin disorders."

Vicept Therapeutics' lead investigational product is V-101, a topical cream for the treatment of the erythema associated with rosacea, which has achieved positive results in two randomised, placebo-controlled phase II studies.

25th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics